Revenue
2021
2022
2023
2024
2025
C4 Therapeutics, Inc. (CCCC)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M | — | — |
| Research & development | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M | $78.4M | $48.1M |
| Operating expenses | $151.2M | $155.2M | $159.8M | $160.6M | $127.9M | $93.6M | $56.8M |
| Operating income | −$115.2M | −$119.6M | −$139.0M | −$129.5M | −$82.1M | −$60.4M | −$35.5M |
| EBITDAderived | −$113.3M | −$117.8M | −$137.2M | −$127.9M | −$80.6M | −$58.8M | −$33.9M |
| Net income | −$105.0M | −$105.3M | −$132.5M | −$128.2M | −$83.9M | −$66.3M | −$34.1M |
| Basic EPSper diluted share | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | -$5.83 | -$31.03 |
| Diluted EPSper diluted share | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | -$5.83 | -$31.03 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 16, 2026Form 4 | REYNO LEONARDChief Medical Officer | SellCommon Stock | 10.0K | $2.22 | $22.2K | 156.4K |
| Feb 18, 2025Form 4 · 10b5-1 | Boyle Scott NChief Business Officer | SellCommon Stock | 669 | $3.15 | $2.1K | 107.8K |
| Feb 14, 2025Form 4 · 10b5-1 | Boyle Scott NChief Business Officer | SellCommon Stock | 490 | $3.15 | $1.5K | 110.8K |